Navigation Links
Oligomerix Awarded Phase IIB Grant From the NIH to Discover Drugs that Inhibit Alzheimer's Disease Progression
Date:9/10/2013

NEW YORK, Sept. 10, 2013 /PRNewswire/ -- Oligomerix, Inc., a privately held company pioneering the development of disease modifying therapeutics for Alzheimer's disease (AD) and related neurodegenerative disorders, announced today the receipt of a two-year Small Business Innovation Research (SBIR) Phase IIB grant for $1.7M from the National Institutes of Health (NIH), National Institute on Aging (NIA).

The proceeds from this grant will be used to extend the Company's research for the development of small molecule drugs aimed specifically at inhibiting tau aggregation at the earliest steps of tau self-association into toxic oligomers in neurons. This approach may be effective in reducing extracellular tau oligomers, including dimers and trimers that have recently been reported to be involved in the spread of tau pathology and to impair memory formation in animal models of AD. A drug that reduces tau oligomer levels may lead to both an improvement in memory and a slowing or complete suspension of disease progression in AD patients and would therefore be a disease-modifying therapeutic.

James Moe, Ph.D., MBA, President and CEO of Oligomerix, stated, "We're pleased to be receiving this support, as it validates our approach and will allow us to advance our programs geared toward inhibiting tau oligomer formation that we believe plays a crucial role in AD progression. This program will allow us to evaluate our lead candidates in animal models of AD and related tauopathies with the goal of selecting candidates for IND enabling studies, a prelude to initial clinical evaluation." 

ABOUT OLIGOMERIX
Oligomerix, Inc. is a biopharmaceutical company focused on the discovery and development of small molecule inhibitors, immunotherapeutic approaches and biomarkers targeting tau oligomers. The Company was founded in 2006 and is headquartered at Audubon Biomedical Science and Technology Park at Columbia University Medical Center and is carrying out its in vivo studies at New York Medical College.  The Company is seeking strategic partners to help accelerate these exciting programs.  For more information, visit www.oligomerix.com.

Certain matters described in this news release may be forward-looking statements subject to risks and uncertainties that could cause actual results to differ materially from those indicated in the forward-looking statements. Such risks and uncertainties include, but are not limited to, the risk of dependence on market growth, competition and dependence on government agencies and other third parties for funding contract research and services.

CONTACTS:
Oligomerix, Inc.
Jack Pasini
Chief Commercial Officer
917-912-4088
jpasini@oligomerix.com

Tiberend Strategic Advisors, Inc.
Andrew Mielach
212-375-2694
amielach@tiberend.com


'/>"/>
SOURCE Oligomerix, Inc.
Copyright©2012 PR Newswire.
All rights reserved

Related medicine technology :

1. NovelMed Awarded NIH Fast Track SBIR Grant for $1.43 Million to Advance Development of its Anti-Complement Antibody for Orphan Disease
2. Carolina Piedmont Capital Awarded VOSB Certification
3. B. Braun Awarded Premier Healthcare Alliance Contract for Dual-Source IV
4. Novan Awarded $7.8 Million Contract by BARDA to Develop a Medical Countermeasure for Thermal Burns
5. Fountain Valley Regional Medical Center Becomes Orange Countys First Hospital Awarded Advanced Certification In Inpatient Diabetes Care
6. aTyr Pharma Awarded Two Patents from USPTO to Support Development of New Therapeutics Based on Physiocrine Biology
7. Arisaph Pharmaceuticals Awarded Phase I STTR Grant To Develop Small Molecule Immune Modulators
8. All Time Medical awarded a Google Trusted Store badge.
9. Dynamic Healthcare Services Awarded Two Oxygen Equipment Competitive Bidding Contracts
10. Instrumentation Laboratory Awarded Premier Healthcare Alliance Contract For Hemostasis Product Line
11. Great Lakes NeuroTechnologies Awarded Patent For Technology To Treat Parkinsons Disease With Brain Stimulation During Sleep
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/24/2016)... 24, 2016 ARANZ Medical  Ltd ... healthcare sector, has been named the Coretex Hi-Tech Emerging Company ... Dr Bruce Davey , CEO of ARANZ ...  It,s really good to be recognised for the work we ... are used in 35 countries around the world from Sub-Saharan ...
(Date:5/24/2016)... BioMarketing as senior vice president of sales, announced Andrea Heslin Smiley , VMS ... company,s business development and sales team, exploring new opportunities for VMS to empower patients ... ... ... ...
(Date:5/24/2016)... May 24, 2016 ... , la première endoprothèse à double ... à l,intervention portant sur les membres inférieurs ... OrbusNeich, entreprise mondiale spécialisée dans la ... la vie, a élargi son portefeuille pour ...
Breaking Medicine Technology:
(Date:5/27/2016)... ... 27, 2016 , ... An educational campaign aimed at everyone ... courtesy of awareness-driven celebrities and thought leaders. It also provides insight to the ... leaders such as Bioness. , As patients feel increasingly concerned about the ...
(Date:5/27/2016)... , ... May 27, 2016 , ... ... scholarships to students studying complementary medicine. Allison Outerbridge is this year’s Life ... award on May 18 at the university’s Student Leadership Awards ceremony. , Outerbridge ...
(Date:5/26/2016)... ... May 26, 2016 , ... Cabot Corporation, ... defective respirators, according to court documents and SEC filings. A jury has ... Tyler v. American Optical Corporation, Case No. BC588866, Los Angeles County, California. The ...
(Date:5/26/2016)... ... 2016 , ... The Woodlands at John Knox Village , Florida’s first ... for living and healing, celebrated its grand opening, today. The Woodlands at John Knox ... by Empowered Staff. , “This is an incredibly fulfilling time for John Knox Village ...
(Date:5/26/2016)... ... May 26, 2016 , ... Dr. James Maisel will ... Long Island Chapter on June 4, 2016, 1:30-3:30 pm at the Farmingdale Public ... Retina Group of New York , is a Board Certified ophthalmologist who ...
Breaking Medicine News(10 mins):